about
Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modificationsComposite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countriesCarbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destructionShort term feeding of a high fat diet exerts an additive effect on hepatocellular damage and steatosis in liver-specific PTEN knockout miceEndogenous catalase delays high-fat diet-induced liver injury in mice.β-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in miceRelationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.Senescence marker protein-30/superoxide dismutase 1 double knockout mice exhibit increased oxidative stress and hepatic steatosis.Pharmacotherapy for alcoholic patients with alcoholic liver diseaseDoes vitamin C deficiency promote fatty liver disease development?Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice.Increased 4-hydroxynonenal protein adducts in male GSTA4-4/PPAR-α double knockout mice enhance injury during early stages of alcoholic liver disease.Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.Modifying Choroidal Neovascularization Development with a Nutritional Supplement in MiceComprehensive Transcriptome Analyses of the Fructose-Fed Syrian Golden Hamster Liver Provides Novel Insights into Lipid Metabolism.The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.Aging Increases Susceptibility to High Fat Diet-Induced Metabolic Syndrome in C57BL/6 Mice: Improvement in Glycemic and Lipid Profile after Antioxidant TherapySignificant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list.Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emerging Role of Lipin-1.The Role of Iron and Iron Overload in Chronic Liver Disease.Iron overload by Superparamagnetic Iron Oxide Nanoparticles is a High Risk Factor in Cirrhosis by a Systems Toxicology Assessment.Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21.Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte InjuryNovel insights into the mechanisms whereby isoflavones protect against fatty liver disease.Therapeutic potential of NADPH oxidase 1/4 inhibitors.Oral Nitrate Reductase Activity Is Not Associated with Development of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Pilot Study.Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis.Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosisModulation of IKKβ/NF-κB and TGF-β1/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice.Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice.Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver.Modeling Nonalcoholic Fatty Liver Disease with Human Pluripotent Stem Cell-Derived Immature Hepatocyte-Like Cells Reveals Activation of PLIN2 and Confirms Regulatory Functions of Peroxisome Proliferator-Activated Receptor Alpha.THE IMPACT OF THE USE OF SYMBIOTICS IN THE PROGRESSION OF NONALCOHOLIC FATTY LIVER DISEASE IN A RAT MODEL.Iron and proinflammatory cytokines in chronic hepatitis C virus infection.Effects of salvianolic acid B on liver mitochondria of rats with nonalcoholic steatohepatitis.Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms.Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non-alcoholic steatohepatitis.Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift.
P2860
Q26824709-00C73E9D-DF1F-46E9-932E-63CD6BD9A3AEQ26828855-96FF0821-C71B-46A3-BAAE-FE94EE1CC47DQ26991952-E9AD2B05-9E35-4207-94A8-0296E4B23C0FQ33599367-D8588DC3-D027-4807-A2FA-4227E81088B9Q33614752-5134263D-80AC-41F6-83CF-C3442CC8C0E5Q33654923-A42B8805-99C2-4DE0-845F-47C212D1E895Q33719929-59A8E96B-93EF-4EB7-8858-19700E9D1744Q33843380-6C81915D-C851-489D-903E-0092190E4878Q34223054-B5BF4E6A-52D4-407F-AEB9-D0540ECBBE5EQ34774959-68E33B36-CCCC-49F1-97F9-1F6CA8ADEDECQ34779049-ED1944F0-C571-4271-8D37-43FF242C687AQ35006116-13B749A7-6021-400D-87C0-985D2452410EQ35138515-9AC215BE-4764-40AF-B5D8-FFA1DAEA1AC7Q35157367-B212F737-5B01-4C8B-8ED1-D32B9AF62914Q35685717-FA201FB8-944B-4EBE-BC4B-436418B3CA83Q36121589-001FDF9B-A499-4AE7-87CC-75CA96E2E0D6Q36246806-CDAE04F2-1F8E-491C-B2FE-5EF2328695CBQ36644107-409C5649-C35A-4739-B686-45AE366CFAC6Q36654125-B377EB24-0411-4380-984A-73E9C466F908Q36932697-AFC7A569-2C6D-421F-8940-96956CE4F383Q37042599-34104B40-565F-4DF4-A07B-B0C9DBBCE05AQ37054424-8CFF353D-9108-49DE-A9C1-6C13C31B7C47Q37315487-2239F2C4-7810-4EC1-A55C-496FA849628CQ37670520-21F44D78-7803-4717-8CCB-CC2A31D12833Q38336275-79BE0BE1-1044-44F9-8571-E2D126AFE911Q38858553-9BC05E28-2C66-43D4-8CE7-FE8702BBE125Q39089800-1D08F44A-29D7-4CD8-888C-EC7DFA073544Q39109576-8C58E34F-B1FE-46FE-A05A-72039291A9DFQ40487416-ED97C5DB-FA5A-4218-B823-88F6449A99FBQ40906850-E78008B0-5573-4374-BA73-0461DF725244Q41419929-DC91072F-30D9-457C-AB95-D0B74479C392Q41784712-D6F3F1BB-1626-4B1D-8F56-4BCE10AD2D67Q42023463-D9A55B7F-823D-4D80-BD39-7115CEC8E714Q42085528-5FD62C69-6D54-405B-ACE6-82CFA9BE37EEQ42280936-5EA925E4-B4B4-4D2F-88C3-0B1F534FD918Q42584295-3B7A7E73-B1CF-48D5-BA7A-D9F80E812139Q42653732-6A56765C-06A1-4035-91FA-04FA4117E8B6Q43635935-CF82982B-02F7-4ABC-8C73-C41FCB10D07AQ46554515-4AC7F741-55D8-42F4-8B5E-F27F6ECE6312Q47105075-B208C426-1DEB-425E-B626-29130102B8A9
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
From fatty liver to fibrosis: a tale of "second hit".
@ast
From fatty liver to fibrosis: a tale of "second hit".
@en
type
label
From fatty liver to fibrosis: a tale of "second hit".
@ast
From fatty liver to fibrosis: a tale of "second hit".
@en
prefLabel
From fatty liver to fibrosis: a tale of "second hit".
@ast
From fatty liver to fibrosis: a tale of "second hit".
@en
P2093
P2860
P356
P1476
From fatty liver to fibrosis: a tale of "second hit".
@en
P2093
Gökcen Basaranoglu
Hakan Sentürk
Metin Basaranoglu
P2860
P304
P356
10.3748/WJG.V19.I8.1158
P407
P577
2013-02-01T00:00:00Z